Clinical trials: Platelets
Smoke Exposure
Platelet-Derived Growth Factors to Enhance Healing and Reduce Post-Extraction Complications in Smokers
This study is a randomized controlled clinical trial with a split-mouth design to evaluate the effect of Advanced Platelet-Rich Fibrin (A-PRF) application on socket healing following dental extractions in smokers.
- Trial name
- NCT07364890
- Testing
- A- PRF
- Where
- Saudi Arabia
- Volunteers
- 12 people
- Sponsor
- King Abdulaziz University
TEETH EXTRACTION
Titanium-Prepared Platelet-Rich Fibrin for Extraction Socket Healing
Alveolar ridge preservation after tooth extraction is important for maintaining bone volume and facilitating future implant placement.
- Trial name
- TPRF-SOCKET (NCT07712497)
- Testing
- Titanium-Prepared Platelet-Rich Fibrin (T-PRF)
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Eskisehir Osmangazi University
Patients on Clopidogrel, Platelets Transfusion
Frequency of Platelets Transfusion & Post-Operative Bleeding Risk in Patients on Clopidogrel Undergoing CABG
The goal of this retrospective cohort study Is to Primarily be platelet transfusion frequency and postoperative bleeding risk, analysis using descriptive and inferential statistics in all eligible patients admitted to the cardiac…
- Trial name
- NCT07600060
- Where
- Pakistan
- Volunteers
- 227 people
- Sponsor
- Aga Khan University
Myelofibrosis, Myeloproliferative Disorders
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
The study consists of two phases: The first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily…
- Conditions
- Myelofibrosis, Myeloproliferative Disorders, Polycythemia Vera, Essential Thrombocythemia
- Trial name
- NCT00745550
- Testing
- SB1518
- Where
- 6 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- S*BIO
Thrombocytopenia, Hepatitis C
Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C
This study will provide chronic hepatitis C patients with low platelets (less than 75x10^9/L) the opportunity to undergo treatment and possible cure of their virus.
- Trial name
- SQUELCH-C (NCT01821625)
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Platelet Aggregation Inhibitors
The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients
Background: Clopidogrel, an antiplatelet prodrug, is widely used for prevention of the recurrent cardiovascular events. CYP2C19 is one of the crucial enzymes for the activation of clopidogrel.
- Trial name
- NCT02711410
- Testing
- Clopidogrel
- Volunteers
- 518 people
- Sponsor
- National Cerebral and Cardiovascular Center, Japan
Gaucher Disease, Thrombocytopathy
Thrombocytopathy in Gaucher Disease Patients
In Gaucher disease type I bleeding is a common presenting symptom, that may manifest itself as frequent nose bleeds, easy bruising but can also cause substantial bleeding after surgical or dental procedures and may occur in…
- Trial name
- NCT01344096
- Where
- 2 sites in Israel
- Volunteers
- 70 people
- Sponsor
- Rabin Medical Center
Regenerative Inflammation
Evaluation of Platelet Rich Fibrin Matrix as Regenerative Material in Intraosseous Defects
Technological advancement has led to the development of concentrated platelets, by means of centrifugation, popularly known as Platelet concentrates which seem to be a convenient approach to obtain autologous growth factors.
- Trial name
- NCT03616925
- Testing
- Platelet Rich Fibrin Matrix kit, surgical open flap debridement
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- KLE Society's Institute of Dental Sciences
Immune Thrombocytopenia
The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of Upadacitinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune…
- Trial name
- NCT07064889
- Testing
- Dexamethasone, Upadacitinib
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Peking University People's Hospital
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003816
- Testing
- anti-thymocyte globulin, busulfan, carboplatin
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Roswell Park Cancer Institute
Pulp Necrosis, Immature Permanent Teeth
PRF and CGF Scaffolds With EDTA in Regeneration
This study evaluated the regenerative outcomes of immature permanent teeth with necrotic pulps treated using three scaffold types-blood clot, platelet-rich fibrin (PRF), and concentrated growth factor (CGF)-combined with either…
- Conditions
- Pulp Necrosis, Immature Permanent Teeth, Open Apex, Periapical Periodontitis
- Trial name
- RET-EDTA-CGF (NCT07265804)
- Testing
- Blood Clot + 5% EDTA, Blood Clot + 17% EDTA, PRF + 5% EDTA
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Kahramanmaras Sutcu Imam University
Stress Urinary Incontinence (SUI)
The Effect of Periurethral Injection of Platelet Rich Plasma Versus Mid-urethral Sling in Treatment of Stress Urinary Incontinence
this study used to compare efficacy between platelet rich plasma periurethral injection versus mid urethral sling ( trans obturator tape ) in treatment of stress urinary incontinence
- Trial name
- NCT07550426
- Testing
- Platelet Rich Plasma, Mid urethral sling ( trans obturator tape)
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Ain Shams University
Aplastic Anemia
Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
This was an open label, non-randomized, phase II study of eltrombopag in combination with rabbit ATG/CsA in subjects with moderate or more severe AA who did not received prior ATG/ALG-based immunosuppressive therapy.
- Trial name
- NCT02404025
- Testing
- Eltrombopag, Rabbit ATG, CsA
- Where
- 11 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Von Willebrand Disease
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
Description of the long-term evolution of patients with von Willebrand disease and treated with Voncento® and of the hemostatic efficacy in the prevention and the treatment of non-surgical bleeding episodes and prevention of…
- Trial name
- OPALE (NCT04657887)
- Testing
- Voncento®
- Where
- 17 sites in France
- Volunteers
- 135 people
- Sponsor
- CSL Behring
Chronic Myeloproliferative Disorders, Leukemia
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00080925
- Testing
- filgrastim, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
This single-arm, open-label exploratory trial aims to evaluate the safety, feasibility, and preliminary efficacy of RN1201 Injection in patients with antibody-mediated diseases, including refractory immune-mediated platelet…
- Trial name
- NCT07072247
- Testing
- CD19 and BCMA-targeted allogeneic CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Thalassemia Major (TM), Thalassemia Intermedia (TI)
Beta-thalassemia and Microparticles
The results will allow us to evaluate the role of MP in the thrombo-embolic risk observed in thalassemic patients and to underline a possible difference between TM and TI.
- Conditions
- Thalassemia Major (TM), Thalassemia Intermedia (TI), Microparticles (MP)Originating From Platelets, Endothelial Cells and Monocytes
- Trial name
- NCT01284738
- Testing
- Physiopathology
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Intrabony Defect, Intrabony Defects in Chronic Periodontitis
Treatment of Intrabony Defect in Patient With Periodontitis Stage III by Using I-PRF and Xenograft
Evaluate of the injectable platelet rich fibrin (I-PRF) with xenograft in Intrabony defects of Periodontitis patient stage III versus Xenograft alone.
- Trial name
- NCT07261878
- Testing
- injectable platelet rich fibrin and xenograft, Xenograft alone
- Where
- 2 sites in Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Immune Thrombocytopenia
A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP
The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsule plus high-dose dexamethasone for the treatment of…
- Trial name
- NCT05023915
- Testing
- dexamethasone, diammonium glycyrrhizinate enteric-coated capsule
- Where
- 2 sites in China
- Volunteers
- 106 people
- Sponsor
- Shandong University
Sepsis
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Sepsis remains a global scourge. Before the SARS-CoV-2 pandemic, the World Health Organization estimated approximately 49 million cases annually, resulting in 11 million deaths.
- Trial name
- PLAQSIRIS (NCT06440317)
- Testing
- Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Bordeaux